Key facts
- This page summarizes Terrence C. Kearney's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Aug 2023, 16:09.
Terrence C. Kearney - 10 Aug 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- Director
- Issuer ticker
- VRTX
- Reported as of
- 10 Aug 2023
- Net transaction value
- -$2,224,600
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2023, 16:09:17 UTC
- Prior SEC filing
- 03 May 2023
- Next SEC filing
- 03 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christiana Stevenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Terrence C. Kearney filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 14 Aug 2023.
Change
- Previous filing in this sequence was filed on 03 May 2023.
- Current net transaction value: -$2,224,600.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Options Exercise
- Transaction value
- $1,275,400
- Shares
- +10,000
- Change %
- +153%
- Price
- $127.54
- Shares after
- 16,536
- Date
- 10 Aug 2023
- Ownership
- Direct
VRTX
transaction
Common Stock
Sale
- Transaction value
- $3,500,000
- Shares
- -10,000
- Change %
- -60%
- Price
- $350.00
- Shares after
- 6,536
- Date
- 10 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 10 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $127.54
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.
Footnote F2
Fully vested.